Dopaminergic cell death precedes iron elevation in MPTP-injected monkeys

Free Radical Biology and Medicine

Volumn 35, Issue 5, 2003, Pages 540-547

  He, Yi ^a,b   Thong, Patricia S ^a   Lee, Timothy ^a   Leong, S K ^a   Mao, Bo Y ^c   Dong, Fang ^a   Watt, Frank ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c SICHUAN UNIVERSITY   (China)

Author keywords

Apoptosis; Dopamine cell death; Free radicals; Iron; Monkeys; MPTP; Nuclear microscopy; Time course

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; IRON; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL DEATH; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; DOPAMINERGIC NERVE CELL; DOPAMINERGIC SYSTEM; IMMUNOHISTOCHEMISTRY; MICROSCOPE; NICK END LABELING; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; SUBSTANTIA NIGRA;

PARKINSONIA;

EID: 0142075349     PISSN: 08915849     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0891-5849(03)00385-X     Document Type: Article

References (40)

1. Chen S., Le W.D., Xie W.J., Alexianu M.E., Engelhardt J.I., Siklos L., Appel S.H. Experimental destruction of substantia nigra initiated by Parkinson's disease immunoglobulins. Arch. Neurol. 55:1998;1075-1080.
2. Kitada T., Asakawa S., Hattori N., Matsumine H., Yamamura Y., Minoshima S., Yokochi M., Mizuno Y., Shimizu N. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature. 392:(6676):1998;605-608.
3. Polymeropoulos M.H., Lavedan C., Leroy E., Ide S.E., Dehejia A., Dutra A., Pike B., Root H., Rubenstein J., Boyer R., Stenroos E.S., Chandrasekharappa S., Athanassiadou A., Papapetropoulos T., Johnson W.G., Lazzarini A.M., Duvoisin R.C., Dilorio G., Globe L.I., Nussbaum R.L. Mutation in the α-synuclein gene identified in families with Parkinson's disease. Science. 276:1997;2045-2047.
4. Sofic E., Lange K.W., Jellinger K., Riederer P. Reduced and oxidized glutathion in the substantia nigra of patients with Parkinson's disease. Neurosci. Lett. 142:1992;128-130.
5. Youdim M.B.H., Ben-Shachar D., Riederer P. Iron-melanin interaction and Parkinson's disease. Trends Pharmacol. Sci. 8:1993;45-49.
6. Youdim M.B.H., Ben-Shachar D., Riederer P. The possible role of iron in etiopathology of Parkinson's disease. Mov. Disord. 8:1993;1-14.
7. Halliwell B., Gutteridge J. Oxygen radicals and the nervous system. Trends Neurosci. 8:1985;22-29.
8. Jenner P. Oxidative stress as a cause of Parkinson's disease. Acta Neurol. Scand. 136:(Suppl.):1991;6-15.
9. Olanow C.W. Oxidation reaction in Parkinson's disease. Neurology. 40:1990;32-37.
10. Fahn S., Cohen G. The oxidant stress hypothesis in Parkinson's disease. Evidence supporting it. Ann. Neurol. 32:1992;804-812.
11. Sofic E., Riederer P., Heinsen H., Beckmann H., Reynolds G.P., Hebenstreit G., Youdim M.B. Increased iron (III) and total iron content in postmortem substantia nigra of parkinsonian brain. J. Neural. Transm. 74:1988;199-205.
12. He Y., Thong P.S.P., Lee T., Leong S.K., Shi C.Y., Wong P.T., Yuan S.Y., Watt F. Increased iron in the substantia nigra of 6-OHDA-induced parkinsonian rats a nuclear microscopy study . Brain Res. 735:1996;149-153.
13. Dexter D.T., Wells F.R., Lees A.J., Agid F., Agid Y., Jenner P., Marsden C.D. Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease. J. Neurochem. 52:1989;1830-1836.
14. Good P.F., Olanow C.W., Perl D.P. Neuromelanin-containing neurons of the substantia nigra accumulate iron and aluminium in Parkinson's disease a LAMMA study . Brain Res. 593:1992;343-346.
15. Riederer P., Sofic E., Rausch W.D., Schmidt B., Reynolds G.P., Jellinger K., Youdim M.B. Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J. Neurochem. 52:1989;515-520.
16. Galazka-Friedman J., Bauminger E.R., Friedman A., Barcikowska M., Hechel D., Nowik I. Iron in parkinsonian and control substantia nigra a Mössbauer spectroscopy study . Mov. Disord. 11:1996;8-16.
17. He Y., Lee T., Leong S.K. Time course of dopaminergic cell death and changes in iron, ferritin, and transferrin levels in the rat substantia nigra after 6-hydroxydopamine (6-OHDA) lesioning. Free Radic. Res. 31:1999;103-112.
18. Mochizuki H., Imai H., Endo K., Yokomizo K., Murata Y., Hattori N., Mizuno Y. Iron accumulation in the substantia nigra of 1-methyl-4-pheyl-1,2,3,6- tetrahydropyridine (MPTP)-induced hemiparkinsonian monkeys. Neurosci. Lett. 168:1994;251-253.
19. Temlett J.A., Landsberg J.P., Watt F., Grime G.W. Increased iron in the substantia nigra compacta of the MPTP-lesioned hemiparkinsonian African green monkey evidence from proton microprobe elemental microanalysis . J. Neurochem. 62:1994;134-146.
20. Thong P.S.P., He Y., Lee T., Watt F. Nuclear microscopic investigations into the elemental changes in the substantia nigra of unilaterally MPTP-lesioned parkinsonian monkeys. Nucl. Instrum. Methods Phys. Res. B. 130:1997;460-465.
21. Napolitano A., Pezzella A., Prota G. New reaction pathways of dopamine under oxidative stress conditions nonenzymatic iron-assisted conversion to norepinephrine and the neurotoxins 6-hydroxydopamine and 6,7- dihydroxytetrahydroisoquinoline . Chem. Res. Toxicol. 12:1999;1090-1097.
22. Hashimoto M., Takeda A., Hsu L.J., Takenouchi T., Masliah E. Role of cytochrome c as a stimulator of α-synuclein aggregation in Lewy body disease. J. Biol. Chem. 274:1999;28849-28852.
23. Oestreicher E., Sengstock G.J., Riederer P., Olanow C.W., Dunn A.J., Arendash G.W. Degeneration of nigrostriatal dopaminergic neurons increases iron within the substantia nigra a histochemical and neurochemical study . Brain Res. 660:1994;8-18.
24. Riederer P., Sofic E., Rausch W.D. Dopaminforschung heute und morgen: L-Dopa in der Zukunft. Riederer P., Umek P. L-Dopa-Substitution der Parkinson-Krankheit: Geschichte-Gegenwart-Zukunft. 1985;127-144 Springer, New York.
25. Uitti R.J., Rajput A.H., Rozdilsky B., Bickis M., Wollin T., Yuen W.K. Regional metal concentrations in Parkinson's disease, other chronic neurological disease, and control brains. Can. J. Neurol. Sci. 16:1989;310-314.
26. Jellinger K., Paulus W., Grundke-Iqbal I., Riederer P., Youdim M.B. Brain iron and ferritin in Parkinson's and Alzheimer's diseases. J. Neural Transm. Park. Dis. Dement. Sect. 2:1990;327-340.
27. Jellinger K., Kienzl E., Rumpelmair G., Riederer P., Stachelberger H., Ben-Shachar D., Youdim M.B. Iron-melanin complex in substantia nigra of parkinsonian brains an x-ray microanalysis . J. Neurochem. 59:1992;1168-1171.
28. Connor J.R., Snyder B.S., Arosio P., Loeffler D.A., LeWitt P. A quantitative analysis of isoferritins in select regions of aged, parkinsonian, and Alzheimer's disease brains. J. Neurochem. 65:1995;717-724.
29. Goto K., Mochizuki H., Imai H., Akiyama H., Mizuno Y. An immuno-histochemical study of ferritin in 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP)-induced hemiparkinsonian monkeys. Brain Res. 724:1996;125-128.
30. Ben-Shachar D., Youdim M.B.H. Intranigral iron injection induces behavioral and biochemical "parkinsonism" in rats. J. Neurochem. 57:1991;2133-2135.
31. Sengstock G.W., Olanow C.W., Menzies R.A., Dunn A.J., Arendash G.W. Infusion of iron into the rat substantia nigra nigral pathology and dose-dependent loss of dopaminergic markers . J. Neurosci. Res. 35:1993;67-82.
32. Ben-Shachar D., Eshel G., Finberg J.P., Youdim M.B. The iron chelatordesferrioxamine (desferal) retards 6-hydroxydopamin-induced degeneration of nigrostriatal dopamine neurons. J. Neurochem. 56:1991;1441-1444.
33. He Y., Lee T., Leong S.K. 6-Hydroxydopamine-induced apoptosis of dopaminergic cells in the rat substantia nigra. Brain Res. 858:2000;163-166.
34. Dexter D.T., Sian J., Rose S. Indices of oxidative stress and mitochondrial function in individuals with incidental Lewy body disease. Ann. Neurol. 35:1994;38-44.
35. Faucheux B.A., Hirsch E.C., Villares J., Selimi F., Mouatt-Prigent A., Javoy-Agid F., Hauw J.J., Agid Y. Distribution of 125I-ferrotransferrin binding sites in the mesencephalon of control subjects and patients with Parkinson's disease. J. Neurochem. 60:1993;2338-2341.
36. Faucheux B.A., Nillesse N., Damier P., Spik G., Mouatt-Prigent A., Pierce A., Leveugle B., Kubis N., Hauw J.J., Agid Y. Expression of lactoferrin receptors is increased in the mesencephalon of patients with Parkinson's disease. Proc. Natl. Acad. Sci. USA. 92:1995;477-486.
37. He Y., Lee T., Leong S.K. Time course and localization of transferrin receptor expression in the substantia nigra of 6-hydroxydopamine-induced parkinsonian rats. Neuroscience. 91:1999;579-585.
38. Loeffler D.A., Connor J.R., Juneau P.L., Snyder B.S., Kanaley L., DeMaggio A.J., Nguyen H., Brickman C.M., LeWitt P.A. Transferrin and iron in normal, Alzheimer's disease, and Parkinson's disease brain regions. J. Neurochem. 65:1995;710-716.
39. Thompson K., Menzies S., Muchenthaler M., Torti F.M., Wood T., Torti S.V., Hentze M.W., Beard J., Connor J. Mouse brains deficient in H-ferritin have normal iron concentration but a protein profile of iron deficiency and increased evidence of oxidative stress. J. Neurosci. Res. 71:2003;46-63.
40. Bartzokis G., Cummings J., Markham C., Marmarelis P., Trecioka L., Tishler T., Marder S. Mintz. J. MRI evaluation of brain iron in earlier- and later-onset Parkinson's disease and normal subject. Magn. Reson. Imaging. 17:1999;213-222.